The phase III TULIP study met its primary endpoint of progression-free survival in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer—demonstrating a statistically significant improvement over physician’s choice.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
